Keji Pharmaceutical-B (02171.HK) issued an announcement. The company's board of directors announced that the abstract of CT041 (a candidate product targeting Claudin18.2 autologous CAR-T cells) has been received for an oral report at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
科济药业-B(02171.HK)：CT041的摘要已被接收于2024年美国临床肿瘤学会年会进行口头报告
Keji Pharmaceutical-B (02171.HK): CT041 abstracts were accepted for oral presentation at the 2024 American Society of Clinical Oncology Annual Meeting
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.